No black box warning on record for Turqoz

As of the latest FDA labeling reviewed, Turqoz (NORGESTREL AND ETHINYL ESTRADIOL) does not carry a black box warning. Standard warnings and precautions still apply — see the full Turqoz medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS 1. Thromboembolic Disorders and Other Vascular Problems Stop Turqoz if an arterial thrombotic event or venous thromboembolic (VTE) event occurs. Stop Turqoz if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. If feasible, stop Turqoz at least 4 weeks before and through 2 weeks after major

No black box warning on record for Turqoz

Other warnings & precautions

WARNINGS 1. Thromboembolic Disorders and Other Vascular Problems Stop Turqoz if an arterial thrombotic event or venous thromboembolic (VTE) event occurs. Stop Turqoz if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately. If feasible, stop Turqoz at least 4 weeks before and through 2 weeks after major

Turqoz Black Box Warning

No black box warning on record for Turqoz

Other warnings & precautions

Turqoz Black Box Warning

No black box warning on record for Turqoz

Other warnings & precautions